All articles by Clinical Trials Arena Team
Clinical Trials Arena Team
Pipeline Moves: Advancement prospects plunge for Parkinson’s drug after trial termination
The Clinical Trials Arena team also reviews assets genetic disorders and metabolic disorders indications.
Pipeline Moves: Advancement prospects plunge for Bristol-Myers’ oncology drug after trial termination
The Clinical Trials Arena team also reviews assets in oncology, genetic disorders and metabolic disorders indications.
Pipeline Moves: Advancement prospects halt for refractory acute myeloid leukaemia therapy after trial suspension
The Clinical Trials Arena team also review assets in oncology and genetic disorders indications.
Pipeline Moves: Advancement prospects plunge for oesophageal adenocarcinoma therapy
The Clinical Trials Arena team also review assets in metabolic disorders, gastrointestinal and oncology indications.
Pipeline Moves: Advancement prospects drop for Novartis oncology drug after trial termination
The Clinical Trials Arena team also review assets in oncology and musculoskeletal disorder indications.
Pipeline Moves: Advancement prospects fall for Pfizer’s RSV therapy after trial termination
The Clinical Trials Arena team also review assets in oncology, ophthalmology, and genitourinary system indications.
Pipeline Moves: Advancement prospects fall for GM1 gene therapy after trial termination
The Clinical Trials Arena team also review assets in the central nervous system, oncology, metabolic and musculoskeletal disorders.
Pipeline Moves: Advancement prospects drop for Alzheimer’s drug after trial termination
The Clinical Trials Arena team also review assets in metabolic disorders, genitourinary system, central nervous system, and oncology indications.
Pipeline Moves: Novo Nordisk Phase III semaglutide completion bumps approval prospects
The Clinical Trials Arena team also investigate assets in ophthalmology, genitourinary system, immunology and oncology indications.
Pipeline Moves: Hengrui Medicine Phase III breast cancer termination lowers approval prospects
The Clinical Trials Arena team also review assets in the central nervous system, cardiology, renal, haematological and other oncology indications.